Australia markets closed

PYC Therapeutics Limited (PYC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0730+0.0030 (+4.29%)
At close: 03:55PM AEST
Full screen
Previous close0.0700
Open0.0710
Bid0.0720 x 42340100
Ask0.0810 x 21464600
Day's range0.0710 - 0.0780
52-week range0.0610 - 0.1900
Volume798,307
Avg. volume677,250
Market cap232.208M
Beta (5Y monthly)0.39
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    PYC Therapeutics Announces Upcoming Poster Presentations Highlighting Preclinical Data from its Ocular and Neurologic Development Programs at TIDES USA and OTS 2021

    PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced two upcoming virtual poster presentations highlighting preclinical data from its ocular and neurologic development programs. The first poster will be presented at TIDES USA 2021, an Oligonucleotide and Peptide Therapeutics c

  • PR Newswire

    PYC Therapeutics Invited to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced it will participate as one of a select group of companies at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, taking place virtually on September 20–23, 2021.

  • PR Newswire

    PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board

    PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced the formation of its ophthalmology-focused Clinical Advisory Board. The Advisory Board will work closely with the Company's executive management team to support the advancement of its rich pipeline of therapeutic candidates